Summary
The addition of Fluosol-DA followed by carbogen breathing increased the antitumor effect of cyclophosphamide as measured by both tumor growth delay and tumor cell survival assays. Under air breathing conditions, cyclophosphamide (100 mg/kg) administered i.p. five times on alternate days produced a tumor growth delay in the FSaIIC fibrosarcoma of 8.0±0.8 days. Adding Fluosol-DA (0.3 ml) to treatment with cyclophosphamide followed by carbogen breathing increased tumor growth delay to 11.4±3.6 days, which was not statistically significantly different from that obtained with the drug plus carbogen breathing without Fluosol-DA. As the dose of Fluosol-DA was increased and administered with drug treatment followed by carbogen breathing for 6 h, increasing tumor growth delays of 15.0±1.5 days, 18.1±1.7 days and 29.4±2.2 days were observed with 0.1 ml, 0.2 ml and 0.3 ml Fluosol-DA, respectively. When 0.1 ml Fluosol-DA was administered in combination with cyclophosphamide and immediately followed by 1 h of hyperbaric oxygen (3 atm), a tumor growth delay of 13.7±1.2 days was observed. With 0.2 ml Fluosol-DA under these conditions, the tumor growth delay increased to 23.2±1.6 days, and with 0.3 ml Fluosol-DA the tumor growth delay was 35.6±3.2 days. Single doses of cyclophosphamide with and without Fluosol-DA (0.3 ml) and various conditions of oxygenation were used in an FSaIIC fibrosarcoma tumor cell survival assay.The addition of Fluosol-DA to this single-dose protocol produced a five- to tenfold increase in tumor cell kill compared to air-breathing drug-treated animals. There was no significant difference in the toxic effect of any of the treatment conditions on bone marrow.
Similar content being viewed by others
References
Ahmed AR, Hombal SM (1984) Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol 11: 1115–1126
Begg AC, Schrieve DC, Smith KA, Terry NHA (1985) Effects of hypoxia, pH and growth stage on cell killing in Chinese hamster V79 cells in vitro by activated cyclophosphamide. Cancer Res 45: 3454–3459
Boon MH, Parsons PG (1984) Cyclophosphamide resistance developed in a human melanoma cell line. Cancer Treat Rep 68: 1239–1246
Borch RF, Millard JA (1987) The mechanism of activation of 4-hydroperoxycyclophosphamide. J Med Chem 30: 427–431
Bradley TR, Sumner MA (1969) Stimulation of mouse bone marrow colony growth in vitro by conditioned medium. Aust J Exp Biol 46: 607–618
Brown JM (1982) On the mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys 8: 675–682
Clement JJ, Gorman MS, Wodinsky I, Catane R, Johnson RK (1980) Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res 40: 4165–4172
Colvin M (1982) The alkylating agents. In: Chabner BA (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 290–293
Dewys WD (1973) A dose-response study of resistance of leukemia L1210 to cyclophosphamide.J Natl Cancer Inst 50: 783–789
D'Incalci M, Torti L, Damia G, Erba E, Morasca L, Garattini S (1983) Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. Cancer Res 43: 5674–5680
Dixon B, Moore JV, Speakman H (1978) Radiobiological hypoxia of a transplanted rat tumour and the effect of treatment with cyclophosphamide. Eur J Cancer 14: 1383–1387
Fischer JJ, Rockwell S, Martin DF (1986) Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int J Radiat Oncol Biol Phys 12: 95–102
Friedman OM, Myles A, Colvin M (1979) Cyclophosphamide and related phosphoramide mustards: current status and future prospects. In: Rosowsky A (ed) Advances in cancer chemotherapy. Dekker, New York, pp 159–164
Frondoza CG Trivedi TP, Humphrey RL (1982) Development of characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. Cancer Treat Rep 66: 1535–1544
Geyer RP (1975) Review of perfluorochemical-type blood substitutes. In: Proceedings of the 10th International Congress for Nutrition: symposium on perfluorochemical artifical blood. Elsevier, Kyoto, pp3–19
Geyer RP (1978) Substitutes for blood and its components. In: Jamieson GA, Greenwalt TJ (eds) Blood substitutes and plasma expanders. Liss, New York, pp 1–21
Geyer RP (1982) Oxygen transport in vivo by means of perfluorochemical preparations. N Engl J Med 307: 304–306
Hill RP, Stanley JA, (1975) The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 35: 1147–1153
Hilton J (1984) Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and- resistant L1210 cells. Biochem Pharmacol 43: 1867–1872
Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209
Kwon CH, Maddison K, Locastro L, Borch RF (1987) Accelerated decomposition of 4-hydroperoxycyclophosphamide by human serum albumin. Cancer Res 47: 1505–1508
McMillan TJ, Stephens TC, Steel GG (1985) Development of drug resistance in a murine mammary tumor. Br J Cancer 52: 823–832
McNally N (1982) Enhancement of chemotherapy. Int J Radiat Oncol Biol Phys 8: 593–599
Pedersen JE, Barron G, Meeker B (1982) The value of combining misonidazole with cyclophosphamide in treating Lewis lung tumors. Int J Radiat Oncol Biol Phys 8: 651–654
Pike BL, Robinson WA (1970) Human bone marrow colony growth in agar-gel. J Cell Physiol 76: 77–84
Rice L, Urano M, Suit HD (1980) The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. Br J Cancer 41 [Suppl 4]: 240–245
Rose CM, Millar JL, Peacock JH (1980) Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by misonidazole. In: Brady LW (ed) Radiation sensitizers: their use in the clinical management of cancer. Masson, New York, pp 250–255
Siemann DW (1982) Potentiation of chemotherapy by hypoxic cell radiation sensitizers — a review. Int J Radiat Oncol Biol Phys 8: 1029–1034
Siemann DW, Sutherland RM (1982) Combinations of cyclophosphamide and misonidazole in the KHT sarcoma. Int J Radiat Oncol Biol Phys 8: 647–650
Sladek NE, Landkamer GJ (1985) Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 45: 1549–1555
Sladek NE, Low JE, Landkamer GJ (1985) Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Cancer Res 45: 625–629
Tannock I (1980) The in vivo interaction of anti-cancer drugs with misonidazole or metronidazole:cyclophosphamide and BCNU.Br J Cancer 42: 871–880
Tannock I (1982) Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interactions of the drugs with radiation. Cancer Res 42: 4921–4926
Tannock IF, Guttman P (1981) Response of Chinese hamster ovary cells to anti-cancer drugs under aerobic and hypoxic conditions. Br J Cancer 43: 245–248
Teicher BA, Holden SA (1987) A survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.Cancer Treat Rep 71: 173–177
Teicher BA, Rose CM (1984) Perfluorochemical emulsion can increase tumor radiosensitivity. Science 223: 934–936
Teicher BA, Rose CM (1984) Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice.Cancer Res 44: 4285–4288
Teicher BA, Rose CM (1986) Effect of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion Fluosol-DA. Int J Radiat Oncol Biol Phys 12: 1311–1313
Teicher BA, Holden SA, Rose CM (1985) Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing. Int J Cancer 36: 585–589
Teicher BA, Holden SA, Jacobs JL (1987) Approaches to defining the mechanism of Fluosol-DA 20%/carbogen enhancement of melphalan antitumor activity. Cancer Res 47: 513–518
Teicher BA, Holden SA, Rose CM (1986) Effect of Fluosol-DA/O2 on tumor cell and bone marrow cytotoxicity of nitrosoureas in mice bearing FSaII fibrosarcoma. Int J Cancer 38: 285–288
Thomas ED (1985) High dose therapy and bone marrow transplantation. Semin Oncol 12 [Suppl 6]: 15–20
Twentyman PR, Kallman RF, Brown JM (1979) The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. II. Cyclophosphamide. Int J Radiat Oncol Biol Phys 5: 1425–1427
Wharam MD, Phillips TL, Kane L, Utley JF (1979) Response of a murine solid tumor to in vivo combined chemotherapy and irradiation. Radiology 109: 451–455
Author information
Authors and Affiliations
Additional information
This work was supported by NIH grant #PO1-CA19589-10, American Cancer Society grant CH 340 (WACS), a grant from the Alpha Therapeutics Co., Los Angeles, CA 90032 and NIH fellowship #5F32-CA07821-02 (SAH)
Rights and permissions
About this article
Cite this article
Teicher, B.A., Herman, T.S., Holden, S.A. et al. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Cancer Chemother. Pharmacol. 21, 286–291 (1988). https://doi.org/10.1007/BF00264193
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00264193